title: Panax notoginseng attenuates experimental colitis in the azoxymethane/dextran sulfate sodium mouse model.
abstract: Patients suffering from inflammatory bowel disease are at a high risk of developing colorectal cancer. To assess the anticancer potential of botanicals, in this study, we evaluated the effects of Panax notoginseng on azoxymethane/dextran sulfate sodium (DSS)-induced colitis. One week after A/J mice received azoxymethane, the animals received DSS for 8 days or were supplemented with P. notoginseng extract, at 30 or 90 mg/kg. DSS-induced colitis was scored with the disease activity index. The severity of the inflammatory lesions was evaluated by a colon tissue histological assessment. The expression of inducible nitric oxide synthase and cyclooxygenase-2 (COX-2) were also explored. We observed that the effects of P. notoginseng on the reduction of colon inflammation, expressed in disease activity index score, were in a dose-related manner (p < 0.01). P. notoginseng inhibited the reduction of the colon length and the loss of bodyweight in dose-related manner (all p < 0.05). The histological assessment of the colitis and inflammatory-related immunohistochemical data also supported the pharmacological observations. Our data suggest that P. notoginseng is a promising candidate in preventing and treating colitis and inflammation-associated colon carcinogenesis.
authors.affiliation: Tang Center for Herbal Medicine Research, University of Chicago, Chicago, IL, 60637, USA; Department of Anesthesia and Critical Care, University of Chicago, Chicago, IL, 60637, USA; State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, 210009, China.
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Wen
authors.forename: Chong-Zhi
authors.initials: CZ
authors.lastname: Wang
authors.forename: Chunhao
authors.initials: C
authors.lastname: Yu
authors.forename: Lei
authors.initials: L
authors.lastname: Zhao
authors.forename: Zhiyu
authors.initials: Z
authors.lastname: Zhang
authors.forename: Adiba
authors.initials: A
authors.lastname: Matin
authors.forename: Yunwei
authors.initials: Y
authors.lastname: Wang
authors.forename: Ping
authors.initials: P
authors.lastname: Li
authors.forename: Shu-Yuan
authors.initials: SY
authors.lastname: Xiao
authors.forename: Wei
authors.initials: W
authors.lastname: Du
authors.forename: Tong-Chuan
authors.initials: TC
authors.lastname: He
authors.forename: Chun-Su
authors.initials: CS
authors.lastname: Yuan
mesh_terms: D000818:Animals; D001397:Azoxymethane; D003092:Colitis / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D003106:Colon / Q000187:drug effects / Q000473:pathology; D051546:Cyclooxygenase 2 / Q000378:metabolism; D016264:Dextran Sulfate; D004195:Disease Models, Animal; D008297:Male; D051379:Mice; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism; D053723:Panax notoginseng / Q000737:chemistry*; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology*; D012503:Saponins / Q000737:chemistry
chemical_list: D010936:Plant Extracts; D012503:Saponins; D016264:Dextran Sulfate; D052247:Nitric Oxide Synthase Type II; C496317:Nos2 protein, mouse; C077623:Ptgs2 protein, mouse; D051546:Cyclooxygenase 2; D001397:Azoxymethane
keywords: AOM/DSS model; Panax notoginseng; colitis; colorectal carcinogenesis; inflammatory bowel disease; notoginseng